A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-κB pathway-Reference-Cited by-同舟云学术

A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-κB pathway

Published:2023-03 Issue:3 Volume:13 Page:1093-1109
ISSN:2211-3835
Container-title:Acta Pharmaceutica Sinica B
language:en
Short-container-title:Acta Pharmaceutica Sinica B

Author:

Yoon Sae-Bom,Hong Hyowon^ORCID,Lim Hee-Jong,Choi Ji Hye,Choi Yoon Pyo^ORCID,Seo Seong Wook,Lee Hyuk Woo,Chae Chong Hak,Park Woo-Kyu,Kim Hyun Young^ORCID,Jeong Daeyoung,De Tran Quang^ORCID,Myung Chang-Seon^ORCID,Cho Heeyeong

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics

Reference97 articles.

1. Integration of B cell responses through Toll-like receptors and antigen receptors;Rawlings;Nat Rev Immunol,2012

2. Oncogenically active MYD88 mutations in human lymphoma;Ngo;Nature,2011

3. The Toll-like receptor adaptor proteins MYD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis;Sacre;Am J Pathol,2007

4. The role of toll-like receptors in rheumatoid arthritis;Huang;Curr Rheumatol Rep,2009

5. Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis;Iwahashi;Arthritis Rheumatol,2004

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive profiling of lncRNAs in the immune response of largemouth bass to Nocardia Seriolae infection;Comparative Immunology Reports;2024-12

2. Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer;Acta Pharmaceutica Sinica B;2024-09

3. PIM1/NF-κB/CCL2 blockade enhances anti-PD-1 therapy response by modulating macrophage infiltration and polarization in tumor microenvironment of NSCLC;Oncogene;2024-07-14

4. Multiple myeloma: signaling pathways and targeted therapy;Molecular Biomedicine;2024-07-04

5. Advances in proteomics in diffuse large B‑cell lymphoma (Review);Oncology Reports;2024-05-09